Register today to attend Antibody Discovery, Selection and Screening Digital Week, our free-to-attend 3-day webinar series featuring antibody discovery, antibody selection, antibody screening, bispecific and multispecific antibodies, bioconjugates, next-generation antibodies, novel platform technologies, enabling technologies, and accelerating antibody discovery to development. To learn about sponsorship of future events, please contact partners@informaconnectls.com

DAY 1 – SEPTEMBER 27, 2021



Advancement of Multispecific MATCH Antibodies as Novel Therapeutics with Disease Modulating Functions and the Potential for Favorable Benefit-risk Profiles
9:00am EDT / 2:00pm BST / 3:00pm CEST

Therapeutic approaches based on Numab’s MATCH platform are presented which aim at multispecific design with superior efficacy and safety. An update on ND021, targeting PD-L1 and 4-1BB will be shown. In addition, the design and preclinical data on multispecifics against other disease targets will be discussed, focusing on the importance of careful selection of key parameters like affinity, valency, epitope and molecular design.

Speaker:

Julia Tietz
Associate Director; Group Leader Pharmacology II
Numab

View More Details +

Combating COVID-19: Identifying an Antibody Drug Candidate for Human Testing In 90 Days
10:00am EDT / 3:00pm BST / 4:00pm CEST

AbCellera screened ~6 million cells from a convalescent COVID-19 patient sample, identifying 440 unique antibodies against SARS-CoV-2. AbCellera’s technology stack was deployed to generate and assess over 250,000 antibody characterization data points, leading to the selection of LY-CoV555 (bamlanivimab), which entered human clinical trials in 90 days from receiving the sample. Bamlanivimab has been used to treat approximately 500,000 patients, preventing more than 20,000 hospitalizations and 11,000 deaths.

Speaker:

Valentine de Puyraimond
Research Scientist, Discovery
AbCellera

View More Details +

The Transcendence of HT-SPR Technology Across Discovery Platforms and its Impact on Time-to-Clinic
11:00am EDT / 4:00pm BST / 5:00pm CEST

In biotherapeutics candidate discovery and development, innovation during the COVID-19 pandemic has been led by a diverse set of strategies used to identify candidates. Within this highly competitive space traditional hybridoma and phage approaches now both contend with and are complemented by NGS and synthetic strategies to meet candidate timelines measured in weeks rather than years. Despite substantial market pressures driving more sophisticated and differentiated approaches, there are stages across these varied workflows where turnkey solutions can be implemented to eliminate bottlenecks. In this talk the role of HT-SPR and its successful enablement of COVID-19 therapeutics will be explored as a technology in biotherapeutics discovery that is deployable in any workflow. Using case studies this talk will highlight touchpoints common across otherwise distinct workflows where leveraging HT-SPR can highlight critical attributes for biotherapeutic candidate selection.

Speaker:

Noah Ditto
Technical Product Manager
Carterra

View More Details +

DAY 2 – SEPTEMBER 28, 2021



Learning a Language Spoken by Nature: Protein Language Model, A Useful Tool for Protein Engineering
9:00am EDT / 2:00pm BST / 3:00pm CEST

Natural antibodies are optimized for general “fitness” by evolution and in vivo selections. Taking natural protein sequences as a language spoken by nature, learning the underlying “grammars” and “semantics” can help various engineering tasks. We have built protein language models (PLMs) trained on >2 billion natural human antibody sequences. The model showed promising results in predicting affinity, expression and functional readout when trained and evaluated on retrospective data.

Speaker:

Yu Qiu, Ph.D.
Senior Principal Scientist
Sanofi

View More Details +

De-risking Antibody Development by Predicting Exposed Liabilities Using High-Throughput Structural Modelling
10:00am EDT / 3:00pm BST / 4:00pm CEST

NGS technologies provide an unparalleled level of sequencing depth that allows for the identification of millions of receptor sequences in a single experiment. However, getting from millions of sequences to a diverse set of developable antibodies with the right therapeutic properties can be incredibly challenging, time-consuming, and requires significant software and computational resources. In this session, we will address how you can predict exposed liability for thousands of antibodies using a secure, intuitive environment to accelerate and de-risk your candidate selection.

Learn how to:

  • Easily perform clustering, phylogeny, and exposed liability analyses in a secure, scalable environment
  • Accelerate candidate selection by exploring multiple antibody characteristics from sequence, assay, and in silico predicted data in a single visualization
  • Leverage exposed liability predictions and developability profiles to de-risk candidate selection

Speaker:

Piotr van Rijssel
Application Specialist
ENPICOM

View More Details +

Superior Leads from a Culminating Dataset Built By Targeted Single B Cell Assays
11:00am EDT / 4:00pm BST / 5:00pm CEST

A rich and comprehensive dataset of hits helps antibody developers select the best leads. SCT’s AbTheneum™ discovery engine delivers a wide dataset of hits with targeted and correlated antibody activities and molecular sequences to help with lead selection.

AbTheneum™ has several customizable assays that can be combined in unrestricted ways to enrich your dataset. Case studies will be presented, including SARS-CoV-2 antibody campaigns. Obtaining AbTheneum™ dataset is fast and enables greater IP protection of your therapeutics.

Speaker:

Chun-Nan Chen, Ph.D.
Chief Executive Officer
Single Cell Technology, Inc.

View More Details +

DAY 3 – SEPTEMBER 29, 2021



Nanobody Discovery, Selection and Screening from Llama Ig Transgenic Mice
9:00am EDT / 2:00pm BST / 3:00pm CEST

Nanobodies, the single variable immunoglobulin domain (VHH) of camelid heavy chain antibodies, exhibit much better solubility than VH domains of human antibodies. AAV are used in gene therapy, oncology, and for producing therapeutic antibodies in vivo. However, their broad tropism still hampers clinical development of AAV. To facilitate the discovery, selection and screening of nanobodies, we have generated llama-IgH transgenic mice. To demonstrate the efficacy of this new nanobody discovery platform, we have generated AAV-specific Nanobodies from immunized llama-IgH transgenic mice. Fusion of such AAV-specific nanobodies to a membrane protein-specific nanobody generates bispecific adaptors that promote the efficacy and specificity of AAV gene therapy vectors.

Speaker:

Thomas Eden, Ph.D., Postdoc
Institute of Immunology
University Medical Center Hamburg-Eppendorf

View More Details +

Leveraging the Immunologic Diversity of PentaMice™ for COVID-19 Antibody Discovery and Vaccine Development
10:00am EDT / 3:00pm BST / 4:00pm CEST

PentaMice™ comprise 5 strains of genetically and immunologically diverse mice that express 42 distinct MHC class II heterodimers (vs. the single IAαbAβb heterodimer utilized by C57Bl/6 mice). We will discuss our success in using PentaMice™ (vs. a single inbred mouse strain) to discover SARS-CoV-2 spike protein antibodies and to help identify COVID-19 vaccines with efficacy across a wide range of genetic backgrounds that is more representative of human immunological diversity.

Speaker:

Brian Zabel, Ph.D.
Vice President, Discovery Immunology
LakePharma, Now a Part of Curia

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details

Day 1

Day 2

Day 3